| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -41.9 | -36.8 |
| EPS (diluted, $ a share) | $-0.68 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KYTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kyverna Therapeutics, Inc.: key numbers
- Share price
- $4.70Close, Nov 17
- Market cap
- $297M
- Shares outstanding
- 63.22MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kyverna Therapeutics, Inc.
All →Kyverna Therapeutics Financial Results
Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.
- Term
- Q3 2026
“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”
Warner Biddle, Chief Executive Officer of Kyverna
Kyverna Therapeutics Clinical Trial Data
Kyverna Therapeutics announced positive one-year topline data from its KYSA-8 registrational trial for miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The results demonstrated durable clinical responses and a favorable safety profile, supporting the company's plan to complete a rolling BLA submission for SPS in Q4 2026.
- Earnings call
- Sep 29, 2026, 10:15 AM ET